13F filer · CIK 1757283
ANDERA PARTNERS
PARIS, I0 · filing since Q4 2025 · last filing Oct 16, 2026
Reported value
$175.7M
$-30.8M vs prior
Positions
7
New / sold out
0 / 1
Added / reduced
0 / 1
Turnover
0.0%
buys $0 · sells $21.1M
Top-10 weight
100.0%
Biggest buys vs Q2 2026
No new or increased positions this quarter.
Biggest sells vs Q2 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | EVOMMUNE INC | -1,294,628 | -93.0% | $-10.7M |
| Sold out | ABIVAX SA | -78,125 | -100.0% | $-10.4M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | KESTRA MED TECHNOLOGIES LTDSHS | 2,728,679 | $77.2M | 43.94% |
| 2 | MINERALYS THERAPEUTICS INCCOM | 1,591,917 | $40.0M | 22.77% |
| 3 | AVALYN PHARMACEUTICALS INCCOM SHS | 929,824 | $26.5M | 15.08% |
| 4 | AGOMAB THERAPEUTICS NVSPONSORED ADS | 1,538,702 | $17.1M | 9.72% |
| 5 | INVENTIVA SAADS | 3,633,181 | $13.4M | 7.63% |
| 6 | EVOMMUNE INCCOM SHS | 97,362 | $804.2K | 0.46% |
| 7 | NYXOAH S ASHS | 522,057 | $720.4K | 0.41% |